Roivant Sciences Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
$ROIV
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 2024
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of Principal Executive Offices)
+44 207 400-3347
(Registrant’s Telephone Number, Including Area Code)
Former Name or Former Address, if Changed Since Last Report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07. |
Submission of Matters to a Vote of Security Holders.
|
On September 10, 2024, Roivant Sciences Ltd. (the “Company”) held its 2024 Annual General Meeting of Shareholders. At that meeting, the shareholders considered and acted
upon four proposals as described in more detail in the Company’s Proxy Statement.
Of 739,183,842 common shares outstanding and entitled to vote as of the close of business on the record date for the meeting, July 17, 2024, the holders of record of
680,116,302 common shares were present at the meeting either in person or by proxy. All proposals on the agenda were approved by the shareholders. Below are the final voting results.
| (1) |
Shareholders re-elected the individuals named below to serve as Class III directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2027, and until
their successors are duly elected and qualified, or until such director’s earlier death, resignation or removal. Election of each director required approval by a plurality of the votes cast.
|
|
Nominee
|
For
|
Withheld
|
Broker Non-Votes
|
|
Ilan Oren
|
409,647,664
|
195,587,109
|
74,881,529
|
|
James C. Momtazee
|
457,800,746
|
147,434,027
|
74,881,529
|
|
Dr. Mayukh Sukhatme
|
602,544,381
|
2,690,392
|
74,881,529
|
| (2) |
Shareholders ratified the appointment of Ernst & Young LLP (“EY”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2025, and to appoint EY as the Company’s auditor for
statutory purposes under the Bermuda Companies Act 1981, as amended, for the fiscal year ending March 31, 2025. Ratification required a simple majority of the votes cast.
|
|
For
|
679,096,310
|
|
Against
|
759,669
|
|
Abstain
|
260,323
|
| (3) |
Shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative
disclosures.
|
|
For
|
540,184,951
|
|
Against
|
64,461,892
|
|
Abstain
|
587,930
|
|
Broker Non-Vote
|
74,881,529
|
| (4) |
Shareholders approved, on a non-binding advisory basis, every one year for the frequency of future non-binding advisory votes to approve the compensation of the Company’s named executive officers. In light
of these voting results, which align with the Board of Directors’ recommendation to the Company’s shareholders, the Company has decided that it will hold an advisory vote on the compensation of the Company’s named executive officers
annually.
|
|
1 Year
|
600,744,457
|
|
2 Years
|
43,363
|
|
3 Years
|
4,070,563
|
|
Abstain
|
376,390
|
|
Broker Non-Vote
|
74,881,529
|
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
ROIVANT SCIENCES LTD.
|
||
|
Date: September 16, 2024
|
By:
|
/s/ Matt Maisak
|
|
Name: Matt Maisak
|
||
|
Title: Authorized Signatory
|
||